The Global Fund has signed a letter of intent with Pfizer for the procurement of up to 6 million treatment courses of the new oral antiviral medicine nirmatrelvir/ritonavir, sold under the name PAXLOVID™, in 2022-2023.
The Global Fund to Fight AIDS, Tuberculosis and Malaria applauds the decision by New Zealand to contribute NZ$8 million to the Global Fund's COVID-19 Response Mechanism (C19RM). The new funding will help provide lifesaving diagnostic tests, treatment...
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria held its 47th Board meeting this week in Geneva. A few months ahead of the Global Fund’s Seventh Replenishment Conference to be hosted by the United States, the Board renewed its ca...
The Global Fund to Fight AIDS, Tuberculosis and Malaria thanks the European Union and Team Europe for their contribution to the Global Fund's COVID-19 Response Mechanism (C19RM). The President of the European Commission, Ursula von der Leyen, announc...
The Global Fund, the United States and Unitaid, together with FIND and other ACT-Accelerator partners, are launching over US$120 million in support to countries for test-and-treat programs to prevent hospitalizations and deaths from COVID-19 for thos...
Ahead of World Malaria Day, 25 April, the Global Fund calls for renewed commitment in the fight against malaria, a disease that now kills one child every minute. After years of steady declines, malaria cases and deaths are on the rise mainly due to s...